Who are Exemestane and GnRH analogue's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/exemestane-and-gnrh-analogue.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Exemestane and GnRH analogue — Competitive Intelligence Brief

Exemestane and GnRH analogue (Exemestane and GnRH analogue) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aromatase inhibitor + GnRH agonist combination. Area: Oncology.

phase 3 Aromatase inhibitor + GnRH agonist combination Aromatase enzyme; GnRH receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Exemestane and GnRH analogue (Exemestane and GnRH analogue) — GBG Forschungs GmbH. Exemestane suppresses estrogen production while a GnRH analogue suppresses ovarian function, providing dual hormonal blockade in premenopausal women with hormone receptor-positive breast cancer.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Exemestane and GnRH analogue TARGET	Exemestane and GnRH analogue	GBG Forschungs GmbH	phase 3	Aromatase inhibitor + GnRH agonist combination	Aromatase enzyme; GnRH receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aromatase inhibitor + GnRH agonist combination class)

GBG Forschungs GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Exemestane and GnRH analogue — Competitive Intelligence Brief. https://druglandscape.com/ci/exemestane-and-gnrh-analogue. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab